Aurelin · AD · Germany · Allergist · captured by Rachel Adeyemi on 19 Jan 2026 · reviewed by Dr. Priya Raman on 23 Jan 2026
Verbatim as captured; never edited
Allergist at Uniklinik Köln raised phase iib efficacy during a advisory board. They asked whether additional data would be presented at the next congress.
Human-approved by Dr. Priya Raman on 23 Jan 2026
Phase IIb efficacy: request for data reported by allergist (DE).
helixor-private-llm-2026.05 · generated 19 Jan 2026, 10:00 UTC
AI summary
Phase IIb efficacy raised by allergist; suggest routing to Medical Communications.
Source spans used by the model
Allergist at Uniklinik Köln raised phase iib efficacy during a advisory board. They asked whether additional data would be presented at the next congress.
| Field | AI suggestion | Final (human-approved) |
|---|---|---|
| Category | Product understanding | Product understanding |
| Function | Medical Communications | Medical Communications |
| Priority | Medium | Medium |
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 5 | 20% | 20.0 |
| Strategic alignment | 5 | 20% | 20.0 |
| Scientific importance | 1 | 15% | 3.0 |
| Urgency | 1 | 15% | 3.0 |
| Novelty | 2 | 10% | 4.0 |
| Actionability | 1 | 10% | 2.0 |
| Confidence | 4 | 5% | 4.0 |
| Breadth of occurrence | 2 | 5% | 2.0 |
| Total | Medium 58 | ||
| Time | Action | User | Field | Change | Reason | Source |
|---|---|---|---|---|---|---|
| 04 Sept 2026, 17:19 UTC | Update | PRDr. Priya Raman | summary | — → Submitted | — | UI |
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
17 Jan 2026 · Dr. Gabriel Vogel, Uniklinik Köln · MSL Rachel Adeyemi
Insight
Reviewed 23 Jan 2026 by Dr. Priya Raman
Action
Publication project · David Chen · In progress
Decision
Outcome
Closure
Duplicate theme merged into strategic objective review.
No other insights on this topic.